Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...

Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads ...

AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...

AstraZeneca and Novartis emphasize US manufacturing capacity to avoid potential pharma tariffs, with Novartis aiming for 100% ...

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

Venture-backed Devoted Health seems to be weathering the Medicare Advantage storm, according to an Endpoints News analysis of ...

Devoted Health shows growth in 2024 with increased membership and revenue while reducing operating losses, contrasting with ...

Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...